| |||||||||||||||||||||||||||||||||||||||
Neural-tube defects such as anencephaly and spina bifida constitute a group of common congenital malformations caused by complex genetic and environmental factors. We have identified three mutations in the VANGL1 gene in patients with familial types (V239I and R274Q) and a sporadic type (M328T) of the disease, including a spontaneous mutation (V239I) appearing in a familial setting. In a proteinprotein interaction assay V239I abolished interaction of VANGL1 protein with its binding partners, disheveled-1, -2, and -3. These findings implicate VANGL1 as a risk factor in human neural-tube defects.
Maternal periconceptional supplementation of folic acid reduces the incidence of neural-tube defects by 50 to 70%.3 Polymorphic variants in genes of the folate and homocysteine pathways have been associated with an increased risk of neural-tube defects, including a common variant (C677T) in the MTHFR gene (5,10-methylene tetrahydrofolate reductase).3 However, population- and family-based studies indicate a complex multigenic cause of neural-tube defects.1 Although no causative gene has been identified in humans, mutated Vangl2 is present in the Loop-tail (Lp) mouse mutant4,5 with a severe defect known as craniorachischisis.6 Vangl2 is the mammalian homologue of the drosophila (fly) gene Stbm/Vang, which is required for establishing planar cell polarity in the developing eye, wing, and leg tissues.7,8
In the fly, planar cell polarity is controlled by a membrane-associated signaling complex composed of several proteins, including Stbm/Vang, frizzled (Fz), disheveled (Dvl), flamingo (Fmi), and prickle (Pk). Activation of planar cell polarity involves an asymmetric redistribution of these core proteins in which cytoplasmic Dvl and Pk are recruited to the plasma membrane, forming complexes with Fz and Stbm/Vang, respectively.9 In vertebrates, a second VANGL gene (VANGL1) has been described. VANGL1 and VANGL2 proteins are highly similar. Each has four predicted transmembrane domains and a cytoplasmic domain that includes a PDZ-binding motif that mediates proteinprotein interaction.10 In mice, Vangl1 and Vangl2 messenger RNAs (mRNAs) are expressed in the ventral and dorsal portions of the developing neural tube, respectively.11
We tested the hypothesis that mutations in the VANGL1 and VANGL2 genes cause neural-tube defects and abrogate the physical interaction of the VANGL1 protein and disheveled proteins.
Methods
Patients
This study included 144 patients with neural-tube defects, including 137 Italian patients with nonsyndromic spinal dysraphisms who were recruited at the Spina Bifida Center of the Gaslini Hospital in Genoa and 7 fetuses with craniorachischisis that were obtained from Groupe Hôpitalier Necker-Enfants Malades in Paris. The Spina Bifida Center of Gaslini Hospital has recruited children with neural-tube defects since 1976, mainly from the north and south of Italy. All mothers of Italian patients lacked periconceptional supplementation of folic acid. Thirteen of the Italian patients had a positive family history documented by clinical records including findings on magnetic resonance imaging (MRI) and radiography, which were obtained from parents of patients whereas all other patients had sporadic disease (Table 1, and Table 1 of the Supplementary Appendix, which is available with the full text of this article at www.nejm.org).
|
All patients and control subjects were Italian with ancestors from all parts of the country, as determined during genetic-counseling sessions. The experimental protocol was approved by the local ethics committee, and written informed consent was obtained from all patients or their parents. We analyzed additional samples from 65 subjects in the control group obtained from the Centre d'Etude du Polymorphisme Humain (CEPH) repository, which contains samples from French, Venezuelan, and Amish persons and also persons from Utah with northwestern European ancestry.
Screening for Mutations
The coding exons of VANGL1 (National Center for Biotechnology Information accession number, NM_138959 [GenBank] ) were amplified by polymerase-chain-reaction (PCR) assay from genomic DNA with the use of primers flanking the exonintron junctions, as described previously.4 Primer sequences are available from the authors on request. The PCR products were purified with the use of a Qiaquick PCR purification kit (Qiagen) and were sequenced with the use of the BigDye Terminator V2.0 cycle sequencing kit and an automated ABI 3700 instrument (Applied Biosystems). All mutations were verified by the dideoxynucleotide termination method and 33P sequencing with the use of the Thermo Sequenase radiolabeled terminator cycle sequencing kit (Amersham Pharmacia Biotech).
Interactions between Proteins
Physical interactions between human VANGL1 and disheveled proteins were monitored as described previously.10 For details, see the Methods section of the Supplementary Appendix.
Results
We identified three Italian patients who were heterozygotic for missense mutations in VANGL1 (V239I, R274Q, and M328T). These mutations were predicted to affect amino acid residues that are conserved across members of the VANGL family. We did not detect these variants in ancestrally matched controls or in CEPH controls. We observed V239I and R274Q in two patients with familial types of disease (Patient 103 and Patient 48, respectively) and M328T in a patient with a sporadic type (Patient 151). The remaining 11 patients with familial types of a neural-tube defect did not carry any disease-specific mutation in the open reading frame of VANGL1. We identified eight other sequence variants in the open reading frame of VANGL1 that were silent (that is, they did not change the predicted amino acid), that were present in both patients with neural-tube defects and control subjects, or that did not affect highly conserved residues (Table 2 of the Supplementary Appendix). On the other hand, we sequenced VANGL2 in both series of patients and identified several variants but none that were predicted to affect protein sequence (data not shown and in agreement with previous findings).11
We detected a missense mutation in VANGL1 that is predicted to result in the substitution of valine with isoleucine at position 239 (V239I) in Patient 103, a 10-year-old Italian girl who had a severe form of caudal regression (type IV of sacral agenesis, according to Pang's classification12) with lipomyeloschisis, anorectal malformation, hydromelia, and tethered spinal cord (Table 1 of the Supplementary Appendix). The girl's mother showed no clinical signs of neural-tube defect, and her brother had a milder form of the disease, dermal sinus. V239I was present in the brother and mother of Patient 103 and was absent in the father and maternal aunt. However, the maternal grandparents did not carry the mutation, indicating that it had arisen de novo in the germ line of one of the maternal grandparents or somatically in the mother and was subsequently transmitted through the mother's germ line (Figure 1A). Additional genotyping confirmed paternity, maternity, and DNA authenticity in all family members (including the paternity and maternity of the mother of the proband) from whom DNA was available (not shown). Valine at position 239 is in the fourth predicted transmembrane domain of the VANGL1 protein (Figure 1C). It is invariant and part of a "VLLE" motif, which is conserved across all known Vangl proteins (Figure 1D). Although a substitution with isoleucine preserves the hydrophobic character of valine, it introduces a bulky side chain, which may have structural or functional consequences.
|
We detected a missense mutation that is predicted to result in the substitution of methionine with threonine at position 328 (M328T) in a 21-year-old woman with sporadic disease; she had myelomeningocele (level L3S1), hydrocephalus, Chiari II malformation, tethered spinal cord, club feet, lumbosacral scoliosis, and sacrococcygeal kyphosis. M328T is also in the predicted cytoplasmic domain of VANGL1 (Figure 1C). The hydrophobic character of methionine is conserved at this position across evolution (Figure 1D). M328T is not a conservative substitution because threonine contains a hydroxyl side chain that substantially increases the hydrophilicity at this position.
Mouse Vangl1 and Vangl2 proteins physically interact with cytoplasmic Dvl1, Dvl2, and Dvl3; in mice, Lp-associated mutations of Vangl2 disrupt this interaction.10 Therefore, we tested the ability of V239I, R274Q, and M328T variants of VANGL1 to interact with the Dvl proteins with use of the yeast two-hybrid system. All VANGL1 and Dvl constructs were stably expressed at similar levels in Saccharomyces cerevisiae (Figure 2A). Our results indicate that VANGL1 interacts with the N-terminal half of Dvl proteins and that this interaction is disrupted either completely (D259E) or partially (S467N) by Lp-associated mutations (Figure 2B). The V239I mutation in VANGL1 abrogated interaction between VANGL1 and all three Dvl proteins, whereas R274Q and M238T had no apparent effect on this interaction in this assay (Figure 2B). We obtained similar results regardless of the "reporter" of this interaction (the secretion of
-galactosidase or the production of
-galactosidase) in diploid yeast cells (Figure 2C and 2D).
|
We have identified three VANGL1 mutations (V239I, R274Q, and M328T) in patients with sporadic and familial neural-tube defects. These three mutations affect residues conserved in Vangl proteins across species. Our findings contrast with those of a previous study in which no disease-specific mutation was identified in VANGL1 in a group of 66 patients with neural-tube defects.11
The phenotype associated with V239I varied among patients. This finding is consistent with the proposed multifactorial model for neural-tube defects; V239I probably has a partial or complete loss-of-function effect and interacts with other genetic loci or unknown environmental factors to modulate the incidence and severity of the defect. Notably, the mother of the proband with the V239I de novo mutation also had the mutation (de novo) but no phenotype for a neural-tube defect, possibly reflecting mosaicism (with respect to cells carrying the mutation) or variable penetrance or expressivity. At the biochemical level, V239I abolishes the interaction of VANGL1 with Dvl proteins, which may compromise the recruitment of Dvl to the plasma membrane and thus perturb molecular signaling during gastrulation and neural-tube closure.
Noncoding regulatory polymorphisms in VANGL1, particularly regulatory variants modulating the level of gene transcription, could also confer susceptibility to neural-tube defects. A thorough analysis of the promoter region of VANGL1 in our series of patients may uncover additional mutations predisposing to the condition. However, the identification of such polymorphisms is challenging in the absence of detailed information on cis-acting sequence elements that regulate temporal and tissue-specific expression of VANGL1 during embryogenesis.
Our results are consistent with studies that underscore the critical role of core planar-cell-polarity genes (Vangl2, Celsr1, Dvl, and Fz) in controlling convergent extension, a process necessary for neural-tube closure.4,5,13,14,15,16 Moreover, it was shown that mutations in Ptk7 interact genetically with Vangl2 in mice that are heterozygous for both mutations and consequently develop neural-tube defects.17 Studying the effect of periconceptional supplementation with folic acid, inositol, and methionine on the emergence of neural-tube defects in these mutants may shed further light on the preventive mechanism associated with these nutrients. Additional tests of association between mutated VANGL1 and neural-tube defects in humans is warranted, as is the systematic genetic and biochemical testing of the other members of the planar-cell-polarity signaling pathway for a role in the cause of this disease.
Supported by a Career Award from the Burroughs Wellcome Fund (to Dr. Wallingford), by a grant from the Gaslini Foundation (to Dr. Capra), by the National Institute of General Medical Sciences, and by grants from the Canadian Institute for Health Research, the Natural Science and Engineering Research Council, Genome Quebec, and Genome Canada (to Drs. Drapeau and Gros).
No potential conflict of interest relevant to this article was reported.
We thank all the patients who participated in this study; the Spina Bifida Association of Italy; and T. Attie-Bitach and M. Vekemans of Hôpital NeckerEnfants Malades, Paris, for their assistance with the craniorachischisis samples.
Source Information
From the Department of Biochemistry, McGill University (Z.K., E.T., J.B., M.M., P.G.), and the Centre for Research in Neuroscience, Research Institute of the McGill University Health Centre, and the Department of Pathology and Cell Biology, University of Montreal (J.R.M., A.R., P.D.) all in Montreal; the Institute of Hereditary Diseases, Minsk, Belarus (I.K.); Unità Operativa di Neurochirurgia, Istituto G. Gaslini, Genoa, Italy (P.D.M., E.M., V.C.); and the Institute for Cellular and Molecular Biology, University of Texas, Austin (J.M.H., J.B.W.). Address reprints requests to Dr. Gros at the Department of Biochemistry, McGill University, 3655 Promenade Sir William Osler, Rm. 907, Montreal, QC H3G 1Y6, Canada, or at philippe.gros{at}mcgill.ca.
References
| |||||||||||||||||||||||||||||||||||||||
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved. |